Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
26 kDa. Protein migrates as 23-26 kDa in reduced SDS-PAGE due to glycosylation
HEK 293 Cells
Greater than 95% by SDS-PAGE
Measured by its ability to inhibit the TNFa mediated cytotoxicity in the L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. The ED50 for this effect is typically 0.05-0.5 µg/mL in the presence of 0.25 ng/mL rhTNFa.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from PBS, pH 7.4, 5-8% mannitol or trehalose
Centrifuge the vial before opening. Reconstitute in sterile PBS, pH 7.4 to 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, store at -20°C.
Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.